StockDuty ← Dashboard Nov 04, 2026 05:55 AM ET
SignalCorporate

Pfizer raises 2026 outlook to $62B-$64B revenue and $2.95-$3.05 adjusted EPS, targeting high single-digit revenue CAGR from 2028-2033

Pfizer raised 2026 revenue and EPS guidance and set 2028-2033 CAGR target.

What happened: Pfizer raised its 2026 outlook to $62B-$64B in revenue and $2.95-$3.05 in adjusted EPS, and said it targets a high single-digit revenue CAGR from 2028 to 2033. Key numbers: 2026 revenue outlook $62B-$64B. 2026 adjusted EPS outlook $2.95-$3.05. High single-digit revenue CAGR targeted for 2028-2033. 32% operational revenue growth in the quarter for launch and acquired products. Why it matters: CEO Albert Bourla cited commercial execution and the 32% operational growth in launch and acquired products as showing the underlying strength of the business. Coverage: 3 outlets in 24h
Pfizer raised its 2026 outlook to $62B-$64B in revenue and $2.95-$3.05 in adjusted EPS, and said it targets a high single-digit revenue CAGR from 2028 to 2033.
CEO Albert Bourla cited commercial execution and the 32% operational growth in launch and acquired products as showing the underlying strength of the business.
Sources